Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Capital Leases (2022 - 2024)

Inhibikase Therapeutics (IKT) has disclosed Capital Leases for 3 consecutive years, with $58330.0 as the latest value for Q1 2024.

  • On a quarterly basis, Capital Leases fell 67.25% to $58330.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $58330.0, a 67.25% decrease, with the full-year FY2023 number at $90124.0, down 56.13% from a year prior.
  • Capital Leases was $58330.0 for Q1 2024 at Inhibikase Therapeutics, down from $90124.0 in the prior quarter.
  • In the past five years, Capital Leases ranged from a high of $232020.0 in Q3 2022 to a low of $58330.0 in Q1 2024.
  • A 3-year average of $147859.9 and a median of $149971.0 in 2023 define the central range for Capital Leases.
  • Peak YoY movement for Capital Leases: plummeted 47.84% in 2023, then tumbled 67.25% in 2024.
  • Inhibikase Therapeutics' Capital Leases stood at $205451.0 in 2022, then crashed by 56.13% to $90124.0 in 2023, then tumbled by 35.28% to $58330.0 in 2024.
  • Per Business Quant, the three most recent readings for IKT's Capital Leases are $58330.0 (Q1 2024), $90124.0 (Q4 2023), and $121013.0 (Q3 2023).